Roch Houot
Professor of Hematology
CHU de Rennes · Rennes, France
French leader in CAR-T and cellular therapy for lymphomas. Directs one of the main French CAR-T centers with significant MCL patient experience.
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.
Blood · Mar 19, 2026
Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.
Blood advances · Jan 13, 2026
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study.
Blood cancer journal · Apr 24, 2025
Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.
Haematologica · Nov 1, 2024
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma.
Blood · Jul 18, 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Mar 1, 2024